Rui-Hua Xu
#129,153
Most Influential Person Now
Researcher
Rui-Hua Xu's AcademicInfluence.com Rankings
Rui-Hua Xucomputer-science Degrees
Computer Science
#5599
World Rank
#5913
Historical Rank
Computational Linguistics
#823
World Rank
#836
Historical Rank
Machine Learning
#1549
World Rank
#1571
Historical Rank
Artificial Intelligence
#1780
World Rank
#1812
Historical Rank
Download Badge
Computer Science
Rui-Hua Xu's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Rui-Hua Xu Influential?
(Suggest an Edit or Addition)Rui-Hua Xu's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Glycolysis inhibition for anticancer treatment (2006) (1381)
- Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? (2019) (1079)
- Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. (2005) (791)
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. (2016) (726)
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. (2015) (543)
- Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. (2017) (516)
- Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. (2014) (499)
- METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma (2019) (399)
- The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer (2019) (395)
- Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism (2006) (390)
- DNA methylation markers for diagnosis and prognosis of common cancers (2017) (304)
- N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis (2019) (258)
- Circular RNA: metabolism, functions and interactions with proteins (2020) (253)
- LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer (2019) (247)
- Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression (2017) (242)
- Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. (2019) (230)
- Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression (2016) (226)
- Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study) (2014) (224)
- Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer (2010) (220)
- Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression (2019) (196)
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) (193)
- Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer (2012) (193)
- Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer (2020) (191)
- Long noncoding RNA XIST expedites metastasis and modulates epithelial–mesenchymal transition in colorectal cancer (2017) (184)
- Pattern of distant metastases in colorectal cancer: a SEER based study (2015) (181)
- Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway (2013) (175)
- Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. (2019) (174)
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. (2021) (169)
- CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis (2018) (150)
- Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. (2017) (150)
- Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential (2014) (149)
- The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021 (2021) (143)
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial (2018) (142)
- LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer (2020) (140)
- Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China (2013) (139)
- A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio (2015) (137)
- High incidence of hepatitis B virus infection in B‐cell subtype non‐Hodgkin lymphoma compared with other cancers (2007) (126)
- Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis (2019) (124)
- Overexpression of the Circadian Clock Gene Bmal1 Increases Sensitivity to Oxaliplatin in Colorectal Cancer (2013) (118)
- Identification of MicroRNA‐214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression (2014) (117)
- NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications (2020) (114)
- Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. (2015) (114)
- CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer (2013) (112)
- Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma (2019) (111)
- Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer (2012) (108)
- APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production (2019) (107)
- Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial (2011) (106)
- Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells (2005) (104)
- Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer (2012) (102)
- Systematic Analysis of the Aberrances and Functional Implications of Ferroptosis in Cancer (2020) (100)
- ABO blood group, hepatitis B viral infection and risk of pancreatic cancer (2012) (99)
- Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition (2019) (99)
- Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. (2019) (96)
- Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer (2018) (95)
- Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications (2018) (95)
- PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma (2018) (91)
- Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming (2020) (90)
- OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action. (2005) (89)
- Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer (2017) (89)
- Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer (2015) (88)
- HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. (2017) (87)
- Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. (2015) (87)
- Effective Elimination of Cancer Stem Cells By a Novel Drug Combination Strategy (2013) (86)
- CircLONP2 enhances colorectal carcinoma invasion and metastasis through modulating the maturation and exosomal dissemination of microRNA-17 (2020) (85)
- Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02) (2021) (84)
- A circRNA signature predicts postoperative recurrence in stage II/III colon cancer (2019) (84)
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. (2022) (83)
- Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. (2018) (80)
- Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. (2011) (78)
- YAP–IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis (2017) (74)
- ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis. (2018) (73)
- Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer (2012) (73)
- Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis (2011) (69)
- Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-Bromopyruvate Propyl Ester (2012) (69)
- Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. (2011) (69)
- Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. (2016) (69)
- CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma. (2016) (69)
- Structure of Schlafen13 reveals a new class of tRNA/rRNA- targeting RNase engaged in translational control (2018) (69)
- microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer (2015) (68)
- Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study (2018) (67)
- ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition (2017) (64)
- Comparison of 6th and 7th AJCC TNM Staging Classification for Carcinoma of the Stomach in China (2011) (62)
- Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma (2008) (62)
- METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway (2020) (62)
- Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. (2021) (62)
- Impact of pretreatment hematologic profile on survival of colorectal cancer patients (2010) (62)
- Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China (2010) (62)
- Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma (2017) (61)
- Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications (2016) (60)
- Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition) (2019) (60)
- Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients (2014) (60)
- The Tumor-Log Odds of Positive Lymph Nodes-Metastasis Staging System, a Promising New Staging System for Gastric Cancer after D2 Resection in China (2012) (59)
- MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan‐cancer (2020) (59)
- HER2‐positive patients receiving trastuzumab treatment have a comparable prognosis with HER2‐negative advanced gastric cancer patients: A prospective cohort observation (2014) (57)
- Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers (2019) (57)
- MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy (2014) (57)
- Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy (2015) (56)
- Fibrinogen promotes malignant biological tumor behavior involving epithelial–mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma (2017) (56)
- DNA polymeraseη protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy (2010) (56)
- Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer (2014) (55)
- L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer (2013) (55)
- Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor‐κB activation (2016) (55)
- Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. (2018) (55)
- Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study (2017) (54)
- Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer. (2014) (54)
- Beclin 1 expression: A predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type (2010) (54)
- Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases (2015) (53)
- Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer (2021) (53)
- Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. (2016) (53)
- Expressions of hypoxia-inducible factor-1α and hexokinase-II in gastric adenocarcinoma: the impact on prognosis and correlation to clinicopathologic features (2011) (51)
- Right- and left-sided colorectal cancers respond differently to cetuximab (2015) (51)
- Elimination of Chronic Lymphocytic Leukemia Cells in Stromal Microenvironment by Targeting CPT with an Anti-Angina Drug Perhexiline (2016) (50)
- Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. (2014) (50)
- The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma (2008) (49)
- Advancing to the era of cancer immunotherapy (2021) (48)
- Detailed analysis of prognostic factors in primary esophageal small cell carcinoma. (2014) (47)
- Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells (2020) (47)
- The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases (2018) (46)
- Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway (2016) (46)
- Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies (2019) (46)
- VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients: The Identification of Chinese Hospitalized Patients' Risk Profile for Venous Thromboembolism (DissolVE‐2)—A Cross‐sectional Study (2019) (46)
- Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer. (2016) (45)
- The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors (2020) (45)
- A Coiled‐Coil Domain Containing 50 Splice Variant Is Modulated by Serine/Arginine‐Rich Splicing Factor 3 and Promotes Hepatocellular Carcinoma in Mice by the Ras Signaling Pathway (2018) (45)
- Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. (2016) (45)
- Comparison of survival and clinicopathologic features in colorectal cancer among African American, Caucasian, and Chinese patients treated in the United States: Results from the surveillance epidemiology and end results (SEER) database (2015) (44)
- β-phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype. (2013) (44)
- Are Risk Factors Associated with Outcomes in Pancreatic Cancer? (2012) (43)
- Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC) (2012) (43)
- Ratio of Metastatic To Resected Lymph Nodes Enhances To Predict Survival In Patients With Stage III Colorectal Cancer (2011) (43)
- 3-D RoI-Aware U-Net for Accurate and Efficient Colorectal Tumor Segmentation (2018) (42)
- Targeting CDH17 Suppresses Tumor Progression in Gastric Cancer by Downregulating Wnt/β-Catenin Signaling (2013) (42)
- Inhibition of Fatty Acid Catabolism Augments the Efficacy of Oxaliplatin-based Chemotherapy in Gastrointestinal Cancers. (2020) (42)
- Decreased expression of the mitochondrial metabolic enzyme aconitase (ACO2) is associated with poor prognosis in gastric cancer (2013) (42)
- Comparison of prognostic nomograms based on different nodal staging systems in patients with resected gastric cancer (2017) (42)
- KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma (2020) (42)
- Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study (2016) (42)
- Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer (2010) (41)
- HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. (2011) (40)
- Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2 (2014) (40)
- qPhos: a database of protein phosphorylation dynamics in humans (2018) (39)
- Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large‐scale, big‐data intelligence platform–based analysis from an endemic area (2017) (39)
- Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB 2 expression (2017) (38)
- Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. (2014) (38)
- Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation (2018) (38)
- The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer (2013) (38)
- Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer (2013) (37)
- Prognostic relevance of BRD7 expression in colorectal carcinoma (2013) (37)
- FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis (2021) (37)
- Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis (2021) (36)
- Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism (2015) (36)
- Impact of marital status on survival of gastric adenocarcinoma patients: Results from the Surveillance Epidemiology and End Results (SEER) Database (2016) (35)
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study (2021) (35)
- Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. (2010) (34)
- Synergy between Auranofin and Celecoxib against Colon Cancer In Vitro and In Vivo through a Novel Redox-Mediated Mechanism (2019) (34)
- The progress of targeted therapy in advanced gastric cancer (2013) (34)
- Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors (2010) (34)
- Annona squamosa Linn: cytotoxic activity found in leaf extract against human tumor cell lines. (2014) (34)
- Clinicopathological characteristics and prognostic analysis of gastric cancer in the young adult in China (2011) (33)
- Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’ (2019) (32)
- The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma (2016) (32)
- [Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer]. (2003) (32)
- Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers (2017) (32)
- VDR–SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment (2020) (32)
- Low preoperative albumin-globulin score predicts favorable survival in esophageal squamous cell carcinoma (2016) (31)
- Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer (2013) (31)
- The Role of Non-Curative Surgery in Incurable, Asymptomatic Advanced Gastric Cancer (2013) (31)
- Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer (2019) (30)
- Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer (2019) (29)
- Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib. (2012) (29)
- Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features (2019) (29)
- MYC-Activated LncRNA MNX1-AS1 Promotes the Progression of Colorectal Cancer by Stabilizing YB1 (2021) (29)
- Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. (2012) (28)
- A relationship between ABO blood groups and clinicopathologic characteristics of patients with gastric adenocarcinoma in China (2011) (27)
- The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p (2021) (27)
- A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer (2008) (27)
- ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). (2021) (26)
- Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation (2014) (26)
- Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer (2016) (26)
- Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer. (2020) (26)
- EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients (2011) (25)
- Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China. (2011) (25)
- Multiparametric MRI and Whole Slide Image-Based Pretreatment Prediction of Pathological Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Multicenter Radiopathomic Study (2020) (25)
- Comparison of survival between right‐sided and left‐sided colon cancer in different situations (2018) (25)
- Prospective observation: Clinical utility of plasma Epstein–Barr virus DNA load in EBV‐associated gastric carcinoma patients (2019) (25)
- S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis (2013) (24)
- Elevated CA19-9 as the Most Significant Prognostic Factor in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy (2015) (24)
- A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance (2017) (24)
- High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance (2012) (23)
- The clinicopathologic relevance and prognostic value of tumor deposits and the applicability of N1c category in rectal cancer with preoperative radiotherapy (2016) (23)
- Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the UK Biobank (2020) (23)
- Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer (2014) (23)
- Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial (2017) (23)
- Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma (2010) (23)
- Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis (2022) (22)
- Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine (2021) (22)
- The genomic landscape of small cell carcinoma of the esophagus (2018) (22)
- Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases (2016) (22)
- Platinum-Based Versus Non-Platinum-Based Chemotherapy as First Line Treatment of Inoperable, Advanced Gastric Adenocarcinoma: A Meta-Analysis (2013) (22)
- PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer (2020) (22)
- S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study (2015) (21)
- DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer (2021) (21)
- Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. (2010) (21)
- The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy (2018) (21)
- Tumor deposits: markers of poor prognosis in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy (2015) (21)
- A CCDC 50 splice variant is modulated by SRSF 3 and promotes hepatocellular carcinoma via the Ras signaling pathway (2018) (21)
- Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c‐Myc/microRNA‐29b Axis (2017) (21)
- Adjuvant Chemotherapy for Elderly Patients with Gastric Cancer after D2 Gastrectomy (2013) (20)
- The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer (2019) (20)
- The lncRNA XIST/miR‐125b‐2‐3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer (2021) (20)
- Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. (2016) (20)
- A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors (2020) (20)
- A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers. (2020) (20)
- Correlation between immune signature and high‐density lipoprotein cholesterol level in stage II/III colorectal cancer (2019) (19)
- Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer (2010) (19)
- HL-FCN: Hybrid loss guided FCN for colorectal cancer segmentation (2018) (19)
- A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer (2015) (19)
- Validation and ranking of seven staging systems of hepatocellular carcinoma (2017) (19)
- Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial. (2020) (18)
- The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile? (2017) (18)
- The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. (2018) (18)
- SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility. (2018) (18)
- Patients with Old Age or Proximal Tumors Benefit from Metabolic Syndrome in Early Stage Gastric Cancer (2014) (18)
- Prognostic analysis in node-negative gastric cancer patients in China (2011) (18)
- ARRY‐334543 Reverses Multidrug Resistance by Antagonizing the Activity of ATP‐Binding Cassette Subfamily G Member 2 (2014) (18)
- JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). (2021) (17)
- gastrointestinal tumours, non-colorectalOlaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study (2016) (17)
- Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis. (2019) (17)
- Phase II clinical trial of S‐1 plus nanoparticle albumin‐bound paclitaxel in untreated patients with metastatic gastric cancer (2018) (17)
- Effect of Raf kinase inhibitor protein expression on malignant biological behavior and progression of colorectal cancer. (2015) (17)
- A Feedback Circuitry between Polycomb Signaling and Fructose-1, 6-bisphosphatase Enables Hepatic and Renal Tumorigenesis. (2020) (17)
- Primary small cell carcinoma of the esophagus: clinicopathological study of 44 cases (2014) (17)
- Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases (2021) (17)
- Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. (2021) (16)
- PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer (2020) (16)
- Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer (2017) (16)
- The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy (2015) (16)
- The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer (2018) (16)
- Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma (2012) (16)
- Treatment patterns and direct medical costs of metastatic colorectal cancer patients: a retrospective study of electronic medical records from urban China (2020) (16)
- A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer. (2015) (16)
- AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation (2019) (16)
- Pathological Assessment of the AJCC Tumor Regression Grading System After Preoperative Chemoradiotherapy for Chinese Locally Advanced Rectal Cancer (2016) (16)
- Phase 2 Study of Capecitabine and Irinotecan Combination Chemotherapy (Modified XELIRI Regimen) in Patients With Advanced Gastric Cancer (2011) (15)
- Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. (2018) (15)
- Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China (2020) (15)
- Genome-wide analysis of Epstein-Barr virus identifies variants and genes associated with gastric carcinoma and population structure (2017) (15)
- Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy (2020) (15)
- RETRACTED ARTICLE: Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer (2019) (15)
- Mutation spectrum of germline cancer susceptibility genes among unselected Chinese colorectal cancer patients (2019) (15)
- Expert opinions on immunotherapy for patients with colorectal cancer (2020) (15)
- Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response (2016) (15)
- Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas (2011) (15)
- Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study. (2018) (14)
- Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy (2010) (14)
- Inhibition of glycolysis in cancer cells (2005) (14)
- CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC). (2017) (14)
- Defeating cancer: the 150 most important questions in cancer research and clinical oncology (2016) (14)
- Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade. (2019) (14)
- Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer (2019) (14)
- Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer (2021) (14)
- First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors. (2020) (14)
- A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients (2018) (13)
- Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms (2016) (13)
- MGMT in colorectal cancer: a promising component of personalized treatment (2016) (13)
- Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer (2019) (13)
- Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial (2019) (13)
- A positive feedback loop consisting of C12orf59/NF-κB/CDH11 promotes gastric cancer invasion and metastasis (2019) (13)
- Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. (2009) (13)
- Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer. (2021) (12)
- Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer (2016) (12)
- Editorial announcement regarding title change of Chinese Journal of Cancer to Cancer Communications (2018) (12)
- Elevated baseline serum lactate dehydrogenase indicates a poor prognosis in primary duodenum adenocarcinoma patients (2018) (12)
- Current management of chemotherapy-induced neutropenia in adults: key points and new challenges (2020) (12)
- Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). (2020) (12)
- Proposal for a New TNM Stage based on the 7th and 8th American Joint Committee on Cancer pTNM Staging Classification for Gastric Cancer (2018) (12)
- Observational cohort study of clinical outcome in Epstein–Barr virus associated gastric cancer patients (2020) (12)
- TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer (2016) (11)
- Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer (2014) (11)
- Lymph node staging systems in patients with gastric cancer treated with D2 resection plus adjuvant chemotherapy (2018) (11)
- The survival benefit of palliative gastrectomy and/or metastasectomy in gastric cancer patients with synchronous metastasis: a population-based study using propensity score matching and coarsened exact matching (2019) (11)
- Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression. (2014) (11)
- [Prognosis of 84 intrahepatic cholangiocarcinoma patients]. (2009) (11)
- Practical considerations in the use of regorafenib in metastatic colorectal cancer (2020) (11)
- Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study (2017) (11)
- Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients (2016) (11)
- [Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy]. (2009) (10)
- O-0023CONCUR: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF REGORAFENIB MONOTHERAPY IN ASIAN PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (MCRC) (2014) (10)
- A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma. (2013) (10)
- Hypermethylation of APC2 Is a Predictive Epigenetic Biomarker for Chinese Colorectal Cancer (2018) (10)
- Expert consensus on maintenance treatment for metastatic colorectal cancer in China (2016) (10)
- Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment (2015) (10)
- Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans-arterial chemoembolization therapy (2017) (10)
- Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value (2016) (10)
- Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer (2017) (10)
- Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients (2020) (10)
- Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study (2021) (10)
- Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab (2016) (10)
- S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial. (2019) (9)
- Antineoplastic activity of Holoptelea integrifolia (Roxb.) Planch bark extracts (in vitro). (2013) (9)
- The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma. (2014) (9)
- Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis: Erratum (2021) (9)
- Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis (2020) (9)
- Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC). (2016) (9)
- Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors (2019) (9)
- Impact of body mass index on survival of esophageal squamous carcinoma patients in southern China. (2015) (9)
- Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (2013) (9)
- Proton pump inhibitor use and the efficacy of chemotherapy in metastatic colorectal cancer: a post hoc analysis of a randomized phase 3 trial (AXEPT). (2021) (9)
- Phase II Study of Biweekly Paclitaxel Plus Infusional 5-Fluorouracil and Leucovorin as First-Line Chemotherapy in Patients With Advanced Gastric Cancer (2011) (8)
- Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer. (2018) (8)
- Role of capecitabine in treating metastatic colorectal cancer in Chinese patients (2014) (8)
- [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy]. (2009) (8)
- Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer (2017) (8)
- SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy. (2022) (8)
- Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma. (2015) (8)
- Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases (2017) (8)
- Phase II study of S-1 plus leucovorin (a new 1-week treatment regimen followed by a 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China. (2012) (8)
- Clinical characterization and prognostic factors of primary lymphoma of bone in case of Chinese patients (2011) (7)
- Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma (2009) (7)
- The extramural metastasis might be categorized in lymph node staging for colorectal cancer (2011) (7)
- Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer (2021) (7)
- [Primary central nervous system lymphoma--a report of 32 cases with literature review]. (2006) (7)
- Prognostic effect of high pretreatment neutrophil to lymphocyte ratio on survival of patients with gastric adenocarcinoma in China (2015) (7)
- Prognostic relevance of Period 1 ( Per 1 ) and Period 2 ( Per 2 ) expression in human gastric cancer (2014) (7)
- The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis (2021) (7)
- Phase II study of S‐1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off (2017) (7)
- [Reverse effect of genetically modified adenovirus H101 on drug-resistance of A549/DDP cells to cisplatin]. (2005) (7)
- A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer. (2017) (7)
- FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer (2017) (7)
- Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors. (2020) (7)
- Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment (2021) (7)
- Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018 (2019) (6)
- Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study. (2019) (6)
- Phase II study of S-1 plus leucovorin (1-week treatment regimen followed by 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China: Comparing results of each country and updating overall survival. (2013) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel (2021) (6)
- Primary pulmonary non‐Hodgkin's lymphoma: A retrospective analysis of 29 cases in a Chinese population† (2010) (6)
- Treatment patterns and outcomes in Chinese gastric cancer patients by HER2 status: a non-interventional registry study (EVIDENCE). (2021) (6)
- [Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma]. (2006) (6)
- Oxaliplatin, fluorouracil and leucovorin (FOLFOX) as first-line chemotherapy for metastatic or recurrent colorectal cancer patients (2007) (6)
- Enzymatically synthesized poly(amino-co-ester) polyplexes for systemic delivery of pcDNA-miRNA-214 to suppress colorectal cancer liver metastasis. (2018) (6)
- GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (2019) (6)
- The emerging role of long non-coding RNAs in the drug resistance of colorectal cancer. (2018) (6)
- Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study (2014) (6)
- Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma (2021) (6)
- Abstract CT184: First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis (2021) (6)
- A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer. (2014) (6)
- Circulating tumor DNA methylation marker MYO1-G for diagnosis and monitoring of colorectal cancer (2021) (5)
- Primary tumor immune score fails to predict the prognosis of colorectal cancer liver metastases after hepatectomy in Chinese populations (2021) (5)
- Recombinant humanised anti-PD-1 monoclonal antibody (JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study (2017) (5)
- Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial (2020) (5)
- A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors. (2018) (5)
- [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma]. (2002) (5)
- 433P A phase Ib/II clinical trial of tolerability, safety and efficacy of regorafenib in combination with toripalimab (a PD-1 antibody) in patients with relapsed or metastatic colorectal cancer (2020) (5)
- Germline mutational profile of Chinese patients under 70 years old with colorectal cancer (2020) (5)
- APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production. (2021) (5)
- [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma]. (2006) (5)
- A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO). (2017) (5)
- 500OCONCUR: A RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF REGORAFENIB (REG) MONOTHERAPY IN ASIAN PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (MCRC). (2014) (4)
- The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy (2016) (4)
- The expression of hepatitis B virus surface antigen in 120 Hodgkin's lymphoma patients. (2010) (4)
- The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries. (2013) (4)
- A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT). (2016) (4)
- AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1). (2021) (4)
- Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial (2020) (4)
- [Progress in chemotherapy for advanced gastric cancer]. (2009) (4)
- Genotyping of IL-8-251 T > A yields prognostic information in patients with gastric carcinoma (2013) (4)
- Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019 (2020) (4)
- O-0012 Prognostic Factors of Overall Survival (OS) in Previously Treated Advanced Gastric Cancer (AGC): Analysis of the Phase 3 Granite-1 Trial (2012) (4)
- Validation of the IMPROVE bleeding risk score in Chinese medical patients during hospitalization: Findings from the dissolve-2 study (2020) (4)
- 2013 Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome (2015) (4)
- Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection (2021) (4)
- P-26 RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma (2020) (4)
- Paradoxical role of CBX 8 in proliferation and metastasis of colorectal cancer (2014) (4)
- Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients (2020) (4)
- [Phase II clinical trial of nedaplatin in advanced non-small cell lung cancer]. (2002) (4)
- Circulating tumour DNAmethylation markers for diagnosis andprognosis of hepatocellular carcinoma (2017) (4)
- The drug treatment research of gastrointestinal cancer in China. (2020) (4)
- Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2−advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW. (2020) (4)
- Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III tri1al. (2020) (4)
- [CEOP regimen in the treatment for non-Hodgkin's lymphoma]. (2007) (4)
- A phase 1 multicenter, dose expansion study of ARX788 as monotherapy in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (ACE-Gastric-01). (2021) (4)
- Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study. (2018) (4)
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. (2020) (4)
- Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3. (2021) (4)
- A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations (2017) (3)
- Can an IL13 -1112 C/T (rs1800925) polymorphism predict responsiveness to neoadjuvant chemoradiotherapy and survival of Chinese Han patients with locally advanced rectal cancer? (2016) (3)
- A first-in-human phase I study of CYH33, a phosphatidylinositol 3-kinase (PI3K) α selective inhibitor, in patients with advanced solid tumors. (2020) (3)
- 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy (2021) (3)
- 2111 A randomized, double-blind, placebo-controlled, multicenter Phase II clinical trial of fruquintinib in patients with metastatic colorectal cancer (mCRC) (2015) (3)
- [Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer]. (2007) (3)
- A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC). (2016) (3)
- Novel Targeted Therapy for Advanced Gastric Cancer (2015) (3)
- [Expression of glycoprotein 90K in non-Hodgkin's lymphoma and its clinical significance]. (2005) (3)
- Pd1 antibody sintilimab for dMMR/MSI-H locally advanced rectal cancer: An open-label, phase 2, single-arm study (cohort A). (2021) (3)
- A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. (2015) (3)
- POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy (2021) (3)
- [Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients]. (2010) (3)
- Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study (2023) (3)
- Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting (2019) (3)
- A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy (2021) (3)
- Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody. (2019) (3)
- [Clinical analysis of liver damage of 116 malignant lymphoma patients with chronic HBV infection after cytotoxic chemotherapy]. (2005) (3)
- PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. (2021) (3)
- Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. (2020) (3)
- The prognostic impact of hypoxia-inducible factor-1α and p-Akt expressions in gastric adenocarcinoma (2008) (3)
- O-0029PHASE III STUDY OF APATINIB IN ADVANCED GASTRIC CANCER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (2014) (3)
- [Significance and prognostic factors in 84 patients with colorectal liver metastases treated with radiofrequency ablation]. (2010) (3)
- A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients (2019) (3)
- O-011Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC) (2015) (3)
- [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]. (2007) (3)
- Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE). (2019) (3)
- Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big-Data Platform (2021) (3)
- Evaluation of serum HER2 extracellular domain in in metastatic gastric or gastroesophageal junction cancer: Correlation with HER2 status by immunohistochemistry and fluorescence in situ hybridization and clinicopathologic parameters. (2013) (2)
- [Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection]. (2009) (2)
- Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer (2016) (2)
- Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial (2022) (2)
- Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. (2014) (2)
- Abstract CT108: HELOISE: phase IIIB randomized multicenter study comparing two trastuzumab (H) dose regimens combined with chemotherapy (CT) as first-line (1L) therapy in patients (pts) with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC): (2016) (2)
- [Progression in palliative chemotherapy for advanced colorectal cancer]. (2008) (2)
- Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer (2019) (2)
- Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA. (2022) (2)
- Evaluation of tumor MET protein expression, MET gene amplification, and HER2 expression in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer. (2015) (2)
- Emerging immunological strategies: recent advances and future directions (2021) (2)
- Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway (2016) (2)
- Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (2022) (2)
- [Efficacy and prognostic analysis on surgical resection of pulmonary metastasis from colorectal cancer]. (2009) (2)
- Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset. (2022) (2)
- Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial (2021) (2)
- [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen]. (2003) (2)
- [Effect of expression of coxsackie and adenovirus receptor on antitumor activity of genetically modified adenovirus]. (2005) (2)
- The Chinese Journal of Cancer is indexed in Science Citation Index (SCI) Expanded (2014) (2)
- Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+ line metastatic colorectal carcinoma (mCRC) phase III trial. (2020) (2)
- Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials (2021) (2)
- [Prognostic analysis of 220 colorectal cancer patients with synchronous liver metastases]. (2006) (2)
- 1186PPhase Ia study of a humanized anti-PD-1 monoclonal antibody (JS001) in Chinese patients with refractory solid tumors (2017) (2)
- Critical role of hexokinase II in 3-Bromopyruvate-induced cell death: A potential target for cancer therapeutics (2006) (2)
- Treatment patterns, effectiveness, and safety of Trastuzumab in Chinese patients with metastatic gastric cancer: Interim analysis of the EVIDENCE registry study. (2017) (2)
- Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis (2020) (2)
- [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status]. (2010) (2)
- Estrogen and its signaling pathway in non-small cell lung cancer(NSCLC) (2009) (2)
- ASO Author Reflections: Radiopathomics Strategy of Combing Multi-scale Tumor Information on Pretreatment to Predict the Pathologic Response to Neoadjuvant Therapy (2020) (2)
- Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. (2015) (2)
- FP14.11 Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study (2021) (2)
- Phase Ia dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors. (2020) (2)
- Continuing single-agent capecitabin as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer. (2015) (2)
- RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluor (2021) (2)
- [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer]. (2007) (2)
- Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors (2022) (2)
- Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes-Reply. (2020) (2)
- Systematic analysis of the transcriptome in small‐cell carcinoma of the oesophagus reveals its immune microenvironment (2020) (1)
- [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma]. (2003) (1)
- [A survival of 103 cases of T-cell non-Hodgkin lymphoma]. (2007) (1)
- [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases]. (2003) (1)
- Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (2022) (1)
- A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study) (2022) (1)
- [Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. (2007) (1)
- [Expression and clinical significance of hypoxia-inducible factor-1alpha in gastric cancer]. (2006) (1)
- [Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma]. (2003) (1)
- Heterogeneity and evolution of tumour immune microenvironment in metastatic gastroesophageal adenocarcinoma (2022) (1)
- Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in FRESCO trial. (2021) (1)
- A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT). (2017) (1)
- Effect of knockdown of eukaryotic initiation factor 4A2 (eIF4A2) on growth, metastasis, and oxaliplatin sensitivity in colorectal cancer. (2018) (1)
- The relationship between HER2 expression and Lauren classification in Chinese gastric cancer patients. (2014) (1)
- Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer (2012) (1)
- Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial. (2019) (1)
- Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer (2021) (1)
- Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. (2023) (1)
- Primary small cell carcinoma of the esophagus: clinicopathological study of 44 cases (2014) (1)
- Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial. (2018) (1)
- Predictive value of primary tumor location (TL) in patients (pts) with pan-RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving chemotherapy (CTX) ± cetuximab or panitumumab (C/P): An updated meta-analysis. (2018) (1)
- Global phase III trial of comparing mXELIRI+BV vs FOLFIRI+Bmab for 2nd line mCRC (AXEPT) Japanese population analysis. (2018) (1)
- IDDF2019-ABS-0289 A circRNA signature predicts postoperative recurrence in stage II/III colon cancer (2019) (1)
- IDDF2019-ABS-0316 Long non-coding RNA CRCAL-2 promotes gastric cancer metastasis by activating wnt/beta-catenin pathway via stabilizing the nuclear transport protein RAN (2019) (1)
- CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer (2013) (1)
- Phase II clinical trial of XELOX as first line treatment for patients with unresectable or metastatic gastric cancer (2007) (1)
- Use of DNA polymerase η protein expression to predict treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. (2010) (1)
- Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China (2013) (1)
- Disease characteristics and treatment patterns of Chinese patients with colorectal cancer: a retrospective study using medical records from China (2019) (1)
- Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma (2012) (1)
- First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors (2022) (1)
- Genome sequencing analysis identifies high-risk Epstein-Barr virus subtypes for nasopharyngeal carcinoma (2018) (1)
- IDDF2019-ABS-0307 Long non-coding RNA TMPO-AS1 regulates oesophageal squamous cell carcinoma metastases through activating GLI1 by Maintaining LAP2a expression (2019) (1)
- Eukaryotic initiation factor 4A2 (EIF4A2) expression in colorectal cancer and prediction of prognosis. (2018) (1)
- LBA3_PRRandomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT) (2017) (1)
- MET amplification occurrence and prediction of unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. (2013) (1)
- p.P476S mutation of RBPJL inhibits the efficacy of anti‐PD‐1 therapy in oesophageal squamous cell carcinoma by blunting T‐cell responses (2020) (1)
- Respiratory Defect and Hypoxia Overcome Drug Resistance Associated with Mitochondrial Inhibition of Glycolysis in Cancer Cells : A Novel Strategy to Updated (2005) (1)
- An open-label phase Ib study to determine safety and preliminary efficacy of oral Lucitanib (AL3810) in patients with locally advanced or metastatic gastric, hepatocellular, nasopharyngeal carcinoma, malignant biliary, and thymic tumors. (2020) (1)
- A new role for PHD in chemotherapy. (2012) (1)
- Results of long-term follow-up for patients with advanced gastrointestinal stromal tumor underwent palliative surgery after tyrosine kinase inhibitors therapy. (2016) (1)
- Clinical response and biomarker analysis of POLARIS-02 a phase II study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with metastatic nasopharyngeal carcinoma. (2020) (1)
- Phase Ia clinical trial of adoptively transferring peripheral blood-derived cytotoxic T lymphocytes targeting individual neo-antigens to treat patients with advanced solid tumor. (2019) (1)
- Evaluation of MET and HER2 expression in primary and metastatic tumor in Chinese advanced gastric cancer patients. (2016) (1)
- Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients (2014) (1)
- Abstract 4242: Systematic transcriptome analysis of small cell carcinoma of esophagus suggests a possibility for immunotherapy (2019) (1)
- Performance of common genetic variants in risk prediction for colorectal cancer in Chinese: A two-stage and multicenter study. (2021) (1)
- Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial. (2018) (1)
- IDDF2019-ABS-0200 Long non-coding RNA LOC148709 regulates PFKFB3-mediated glycolytic reprogramming in esophageal squamous cell carcinoma (2019) (1)
- Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study (2022) (1)
- A phase Ib/II study of fruquintinib in combination with paclitaxel as the second‐line therapy for advanced gastric cancer (2022) (1)
- Correction: ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis. (2019) (1)
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023) (1)
- [Preliminary report of semimonthly 5-fluorouracil/leucovorin combined with paclitaxel in treatment of advanced gastric cancer (AGC)]. (2003) (1)
- Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW. (2023) (1)
- Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer (2014) (1)
- A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer. (2021) (1)
- Correction: Targeting CDH17 Suppresses Tumor Progression in Gastric Cancer by Downregulating Wnt/β-Catenin Signaling (2019) (1)
- IDDF2019-ABS-0290 IGF2BP2 facilitates tumor progression via an m6A-dependent mechanism in colorectal carcinoma (2019) (1)
- First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up. (2023) (1)
- The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis (2021) (1)
- Circulating tumor DNA as a promising biomarker of relapse risk for stage II-III colorectal cancer. (2020) (1)
- Chemo-immunotherapy in advanced esophageal squamous cell carcinoma: present and future (2023) (1)
- A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer. (2020) (1)
- 1711P Real-world study of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal tumors (2021) (1)
- 478P RAS mutation clearance in patients with metastatic colorectal cancer (2020) (1)
- Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. (2015) (0)
- Clinical features of hypersensitivity reactions to oxaliplatin among Chinese patients with colorectal cancer (2010) (0)
- Abstract 2345: The genomic landscape of small cell carcinoma of the oesophagus (2018) (0)
- IDDF2019-ABS-0245 Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer (2019) (0)
- Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study. (2018) (0)
- Circulating tumor DNA to monitor treatment response and investigate resistance mechanism in BRAF inhibitor treated colorectal cancer patients. (2020) (0)
- Incidence rate and clinical-pathological features of hereditary diffuse gastric cancer patients in China. (2017) (0)
- 376TiPA study of multiple-antigen specific cellular therapy in vitro combined with PD-1 antibody technology (MASCT-I) in patients with advanced solid tumors (2017) (0)
- Dissimilarities of Regression Between Primary Tumor and Regionally-Involved Lymph Nodes in Locally Advanced Non–Small Cell Lung Cancer Treated By Concurrent Chemoradiotherapy (2018) (0)
- 1498TiP A multi-center, randomized, open-label, phase III study of sintilimab + ramucirumab as 1st-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-106) (2020) (0)
- A phase II clinical trial of toripalimab in advanced solid tumors with POLE/POLD1 mutation. (2023) (0)
- IDDF2020-ABS-0110 lncRNA MNX1-AS1 promotes the progression of colorectal cancer through stabilizing YB1 (2020) (0)
- Predictive Biomarkers and Personalized Medicine EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients (2011) (0)
- Proton Pump Inhibitor Use and the Efficacy of Capecitabine and Fluorouracil in Metastatic Colorectal Cancer: A Post Hoc Analysis of the AXEPT Randomised Phase III Trial (2020) (0)
- Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China (2020) (0)
- CircLONP2 enhances colorectal carcinoma invasion and metastasis through modulating the maturation and exosomal dissemination of microRNA-17 (2020) (0)
- Oxaliplatin, fluorouracil and leucovorin(FOLFOX) as the first-line chemotherapy in metastatic or recurrent colorectal cancer (2007) (0)
- Abstract 5092: Predictive biomarkers for the efficacy of PD-1 inhibitors plus chemotherapy for gastric/gastroesophageal junction cancer in first-line setting (2022) (0)
- A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors. (2023) (0)
- Abstract 124: P21-activated protein kinase 1 high expression is a positive prognostic factor in human primary and metastatic pancreatic cancer (2015) (0)
- Reply to 'Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients' by C. Cremolini et al. (2016) (0)
- Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC). (2018) (0)
- Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST). (2022) (0)
- 223PEfficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study (2015) (0)
- Chinese Journal of Cancer reviewer acknowledgement 2015 (2016) (0)
- IDDF2019-ABS-0292 Nucleus-translocated GCLM facilitates tumor progression through increasing transcription of OCT4 in colorectal carcinoma (2019) (0)
- Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor. (2022) (0)
- IDDF2020-ABS-0118 Long non-coding RNA LRTIS regulates MLL1-mediated immunocheckpoint remodelling in esophageal squamous cell carcinoma (2020) (0)
- A prospective multicenter observational study of bevacizumab for the treatment of metastatic colorectal cancer in Chinese patients (Obtain study). (2018) (0)
- Preliminary Validation of an IMRT Target Volume Delineation Protocol for Patients with Locally Advanced Gastric Cancer Receiving Preoperative Chemoradiation in Comparison with Preoperative Chemotherapy (2019) (0)
- PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer (2020) (0)
- CMAR_A_197052 3993..4003 (2019) (0)
- Abstract CT058: TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors (2023) (0)
- Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in a phase II clinical trial. (2018) (0)
- IDDF2019-ABS-0235 METTL3 as a potential cancer prognostic marker promotes the proliferation and metastasis of gastric cancer cells (2019) (0)
- Neoadjuvant Treatment for Locally Advanced Colon Cancer (2019) (0)
- METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma (2019) (0)
- Short-term efficacy of Cetuximab-contained regimen on patients with advanced gastrointestinal (noncolorectal) cancer: Experiences of 16 patients in single institute (2009) (0)
- Analysis of therapeutic effect and prognostic factors of non-small cell lung cancer leptomeningeal metastasis patients treated by epidermal growth factor receptor tyrosine kinase inhibitors (2017) (0)
- Expression and clinical significance of ATP7A in non-small cell lung cancer (2012) (0)
- Abstract 5407: MicroRNA expression analysis of advanced colorectal cancer reveals a microRNA signature with prognostic and predictive value (2018) (0)
- Phase II Study of S-1 Plus Leucovorin (New 1 Week Treatment Regimen Followed by 1 Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China (2012) (0)
- An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments. (2023) (0)
- Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel as first-line chemotherapy for patients with metastatic gastric cancer. (2016) (0)
- Abstract 4161: Germline mutational profileof Chinese patients with colorectal cancer and diagnosed lower than 70 years (2019) (0)
- Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study (2021) (0)
- Identification of “regulation of RhoA activity panel” as a prognostic and predictive biomarker for gastric cancer (2020) (0)
- Abstract B112: ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2. (2013) (0)
- Abstract 4266: Potential role of reactive oxygen species in affecting tumorigenicity of glioblastoma stem cells (2010) (0)
- Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression (2016) (0)
- A retrospective study on oxaliplatin combined with fluoropyrimidines for advanced small bowel adenocarcinoma (2012) (0)
- Corrigendum to "Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis" [Cancer Lett. 380 (2016) 87-97]. (2020) (0)
- 142OSingle-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of mCRC (2015) (0)
- The efficacy and safety of FOLFIRI+BEV/mXELIRI+BEV by UGT1A1 polymorphisms in metastatic colorectal cancer AXEPT trial (2019) (0)
- IDDF2018-ABS-0184 LNCRNA AGPG regulates anabolism remodelling through affecting PFKFB3 stability in escc (2018) (0)
- The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer (2013) (0)
- An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. (2023) (0)
- Relationship of HER2 alteration and MSI status in colorectal adenocarcinoma. (2021) (0)
- Treatment of hodgkin’s disease with chemotherapy Based-Regimens: Long-term follow-up results with 295 patients (2004) (0)
- A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio (2015) (0)
- PD-1 antibody (Camrelizumab) for metastatic EBV positive gastric cancer: A prospective single-arm, open-label, phase 2 trial. (2021) (0)
- Systematic Pan-Cancer Analysis Reveals the Functional Roles of Ferroptosis Across Cancers (2019) (0)
- [Phase II clinical trial of oxaliplatin alone for refractory advanced colorectal cancer]. (2003) (0)
- Differential association of proton pump inhibitors with efficacy of capecitabine and 5-fluorouracil in metastatic colorectal cancer: A post-hoc analysis from AXEPT phase III trial. (2020) (0)
- 204PPhase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway (2015) (0)
- The progress of targeted therapy in advanced gastric cancer (2013) (0)
- Immunotherapy in gastrointestinal cancers: advances, challenges, and countermeasures. (2023) (0)
- [Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer]. (2009) (0)
- Study on Big Data-Supported Clinical Oncology (2019) (0)
- IDDF2018-ABS-0231 Acidosis promotes the stemness of cancer stem cells through vitamin d-vitamin d receptor signalling pathway in colorectal cancer (2018) (0)
- Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside in prevention of oxaliplatin-induced neurotoxicity in stage II/III colorectal cancer patients. (2019) (0)
- Raf kinase inhibitor protein (RKIP) expression in stage II colorectal cancer and its clinical significance (2010) (0)
- JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (2021) (0)
- Research on the Treatment of Colorectal Cancer Based on Network Pharmacology and Molecular Docking (0)
- The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors (2020) (0)
- Appraisal of prognostic interaction between sidedness and histology in colon cancer: A population-based study. (2018) (0)
- Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study. (2023) (0)
- A Randomized, Controlled Phase III Trial of Docetaxel, Cisplatin and Fluorouracil (DCF) versus Cisplatin Plus Fluorouracil (CF) as First-Line Therapy in Chinese advanced Gastric Cancer (2012) (0)
- Systematic Analyses Reveals the Functional Roles of Ferroptosis Across Cancers (2020) (0)
- DNA Methylation-based Biomarkers in Urological Cancers (2013) (0)
- Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial. (2021) (0)
- Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapeIRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial. (2019) (0)
- Oxaliplatin reintroduction in colorectal cancer patients following disease progression after adjuvant oxaliplatin-based chemotherapy (2012) (0)
- Correction: Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer (2021) (0)
- Correction to: Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression (2021) (0)
- Translating Basic Cancer Discoveries to the Clinic. (2020) (0)
- Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer (2022) (0)
- Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study (2017) (0)
- Efficacy of PD-1/PD-L1 inhibitor-based therapies in refractory microsatellite instability (MSI)-unselected metastatic colorectal cancer (mCRC): A network meta-analysis (NMA) of randomized controlled trials (RCTs). (2019) (0)
- Association between lymph node examination and nodal staging for pancreatic adenocarcinoma: A population-based analysis. (2017) (0)
- Circulating tumor DNA and recurrence risk in stage II-III gastric cancer. (2022) (0)
- A multiple centers real-world study of regorafenib treatment modalities in Chinese metastatic colorectal cancer patients. (2022) (0)
- [Progression of immunotherapy in gastric cancer]. (2016) (0)
- Abstract 2697: A novel therapeutic strategy to effectively kill CLL cells in stromal microenvironment by targeting lipid metabolism (2014) (0)
- A real-world evidence of ef fi cacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients (2019) (0)
- Author’s response to reviews Title: Disease characteristics and treatment patterns of Chinese patients with colorectal cancer: a retrospective study using medical records from China Authors: (2020) (0)
- IDDF2019-ABS-0314 RNA-sequencing identify C1/C2 molecular classification and a novel lncRNA of duodenum adenocarcinoma (2019) (0)
- 1052PDFirst-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial (2017) (0)
- IDDF2020-ABS-0119 Dissecting the molecular mechanism and clinical significance for regulating the malignant progression of gastric cancer by HIPK3 (2020) (0)
- Relationship between prediagnostic body mass index trajectory and colorectal adenomas: an analysis of the PLCO cancer screening trial (2020) (0)
- Prognostic performance of lymph node staging systems in patients with resectable gastric cancer: Comparison of population-based nomograms. (2016) (0)
- 進行胃癌患者に対するカペシタビンおよびイリノテカン併用化学療法(修正XELIRIレジメン)の第2相研究(中国) (2011) (0)
- Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. (2022) (0)
- [Prognostic analysis of 62 cases of nasal NK/T-cell lymphoma]. (2006) (0)
- Abstract 2014: Radiopathomics strategy combining multiparametric MRI with whole-slide image for pretreatment prediction of tumor regression grade to neoadjuvant chemoradiotherapy in rectal cancer (2020) (0)
- Expression of CD117 and PDGFRa in extranodular NK/T cell lymphoma (nasal type) (2006) (0)
- [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality]. (2002) (0)
- The Role of Maintenance Therapy in Metastatic Colorectal Cancer. (2020) (0)
- Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (2022) (0)
- The tumor-log odds of positive lymph nodes-metastasis staging system, a new staging system for gastric cancer after D2 resection in China. (2012) (0)
- Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (2022) (0)
- Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). (2023) (0)
- 142TiPA prospective multi-center study to investigate the EGFR-TKI resistance profile, treatment algorithm and clinical outcome in Chinese patients with advanced EGFRm+ NSCLC who have received prior first generation EGFR TKI (PRECENT study, CCTC-1601, NCT02988141) (2017) (0)
- The preliminary results of treatment ofadvanced and recurrent malignant lymphoma by beac regimen supported with autologous hematopoietic stem cells transplantation (2002) (0)
- A retrospective clinical analysis of 30 patients with primary testicular non-Hodgkin lymphoma (2006) (0)
- A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. (2019) (0)
- First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis (2022) (0)
- Correction to: CircLONP2 enhances colorectal carcinoma invasion and metastasis through modulating the maturation and exosomal dissemination of microRNA-17 (2021) (0)
- Advances in Targeted Cancer Therapy (2016) (0)
- Outcome of hepatectomy for patients with multiple hepatic metastases from colorectal cancer (2010) (0)
- Incidence rate and clinic-pathologic features of EBV-associated gastric carcinoma in China. (2018) (0)
- Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer (2013) (0)
- Artificial intelligence applications in upper gastrointestinal cancers - Authors' reply. (2020) (0)
- Abstract LB-58: Role of mitochondrial ROS in activation of glioma stem cells and promotion of cancer development (2014) (0)
- Phase III study of trifluridine/tipiracil versus placebo in Asian patients with metastatic colorectal cancer (TERRA study): Country subgroup (2017) (0)
- Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. (2022) (0)
- Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials (2022) (0)
- IDDF2018-ABS-0122 MICRORNA expression analysis of advanced colorectal cancer reveals a microrna signature with prognostic and predictive value (2018) (0)
- Zero difference in survival between stable disease and good response in patients with advanced colorectal cancer after first-line chemotherapy (2013) (0)
- Watch-and-wait Strategy against Surgical Resection for Rectal Cancer Patients with Complete Clinical Response after Neoadjuvant Chemoradiotherapy (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Rui-Hua Xu?
Rui-Hua Xu is affiliated with the following schools:
